Advertisement

Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy

Published:November 09, 2016DOI:https://doi.org/10.1016/j.ijrobp.2016.08.011

      Purpose

      To report the toxicity and preliminary clinical outcomes of a prospective trial evaluating 19-Gy, single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer.

      Methods and Materials

      A total of 63 patients were treated according to an institutional review board-approved prospective study of single-fraction HDR brachytherapy. Eligible patients had tumor stage ≤T2a, prostate-specific antigen level ≤15 ng/mL, and Gleason score ≤7. Patients with a prostate gland volume >50 cm3 and baseline American Urologic Association symptom score >12 were ineligible. Patients underwent transrectal ultrasound-guided transperineal implantation of the prostate, followed by single-fraction HDR brachytherapy. Treatment was delivered using 192Ir to a dose of 19 Gy prescribed to the prostate, with no additional margin applied.

      Results

      Of the 63 patients, 58 had data available for analysis. Five patients had withdrawn consent during the follow-up period. The median follow-up period was 2.9 years (range 0.3-5.2). The median age was 61.4 years. The median gland volume at treatment was 34.8 cm3. Of the 58 patients, 91% had T1 disease, 71% had Gleason score ≤6 (29% with Gleason score 7), and the median pretreatment prostate-specific antigen level was 5.1 ng/mL. The acute and chronic grade 2 genitourinary toxicity incidence was 12.1% and 10.3%, respectively. No grade 3 urinary toxicity occurred. No patients experienced acute rectal toxicity grade ≥2, and 2 experienced grade ≥2 chronic gastrointestinal toxicity. Three patients experienced biochemical failure, yielding a 3-year cumulative incidence estimate of 6.8%.

      Conclusions

      Single-fraction HDR brachytherapy is well-tolerated, with favorable preliminary biochemical and clinical disease control rates.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martinez A.
        • Gustafson G.
        • Gonzalez J.
        • et al.
        Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 53: 316-327
        • Demanes D.J.
        • Rodriguez R.
        • Schour L.
        • et al.
        High dose rate intensity modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10-year results.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1306-1316
        • Martinez A.
        • Gonzalez J.
        • Ye H.
        • et al.
        Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
        Int J Radiat Oncol Biol Phys. 2011; 79: 363-370
        • Brenner D.
        • Martinez A.
        • Edmundson G.
        • et al.
        Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
        Int J Radiat Oncol Biol Phys. 2002; 52: 6-13
        • Mirabell R.
        • Roberts S.
        • Zubizarreta E.
        • et al.
        Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
        Int J Radiat Oncol Biol Phys. 2012; 82: e17-e24
        • Jawad M.
        • Dilworth J.
        • Gustafson G.
        • et al.
        Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2016; 94: 657-666
        • Ghilezan M.
        • Martinez A.
        • Gustafson G.
        • et al.
        High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: Preliminary toxicity data.
        Int J Radiat Oncol Biol Phys. 2012; 83: 927-932
        • Kupelian P.
        • Willoughby T.
        • Reddy C.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1424-1430
        • Coote J.
        • Wylie J.
        • Cowan R.
        • et al.
        Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: Analysis of toxicity.
        Int J Radiat Oncol Biol Phys. 2009; 74: 1121-1127
        • Aluwini S.
        • Pos F.
        • Schimmel E.
        • et al.
        Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial.
        Lancet Oncol. 2015; 16: 274-283
        • Pollack A.
        • Walker G.
        • Horwitz E.
        • et al.
        Randomized trial of hypofractionated external beam radiotherapy for prostate cancer.
        J Clin Oncol. 2013; 31: 3860-3868
        • Hoffman K.
        • Voong K.
        • Pugh T.
        • et al.
        Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial.
        Int J Radiat Oncol Biol Phys. 2014; 88: 1074-1084
        • Lee W.R.
        • Dignam J.
        • Amin M.
        • et al.
        Randomized phase III non-inferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.
        J Clin Oncol. 2016; 34: 2325-2332
        • Lukka H.
        • Stephanie P.
        • Bruner D.
        • et al.
        Patient reported outcomes in NRG Oncology/RTOG 0938, a randomized phase 2 study evaluating 2 ultrahypofractionated regimens for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2016; 94: 2
        • King C.
        • Brooks J.
        • Gill H.
        • et al.
        Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82: 877-882
        • Chen L.
        • Suy S.
        • Uhm S.
        • et al.
        Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience.
        Radiat Oncol. 2013; 8: 58
        • Madsen B.
        • Hsi R.
        • Pham H.
        • et al.
        Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1099-1105
        • Katz A.
        • Kang J.
        Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.
        Front Oncol. 2014; 4: 240
        • Hannan R.
        • Tumati V.
        • Xie X.
        • et al.
        Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial.
        Eur J Cancer. 2016; 59: 142-151
        • Hauswald H.
        • Kamrava M.
        • Fallon J.
        • et al.
        High-dose-rate monotherapy for localized prostate cancer: 10-Year results.
        Int J Radiat Oncol Biol Phys. 2016; 94: 667-674
        • Yoshioka Y.
        • Suzuki O.
        • Isohashi F.
        • et al.
        High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: Clinical results for a median 8-year follow-up.
        Int J Radiat Oncol Biol Phys. 2016; 94: 675-682
        • Durkee B.
        • Buyyounouski M.
        The case for prostate brachytherapy in the affordable care act era.
        Int J Radiat Oncol Biol Phys. 2015; 91: 465-467
        • Shah C.
        • Lanni T.
        • Ghilezan M.
        • et al.
        Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
        Brachytherapy. 2012; 11: 441-445
        • Hoskin P.
        • Rojas A.
        • Ostler P.
        • et al.
        High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity.
        Radiother Oncol. 2014; 110: 268-271
        • Prada P.
        • Cardenal J.
        • Blanco A.G.
        • et al.
        High-dose-rate brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results.
        Radiother Oncol. 2016; 119: 411-416
        • Zelefsky M.
        • Leibel S.
        • Gaudin P.
        • et al.
        Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 491-500
        • Vogelius I.
        • Bentzen S.
        Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?.
        Int J Radiat Oncol Biol Phys. 2013; 85: 89-94
        • Kuban D.
        • Tucker S.
        • Dong L.
        • et al.
        Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Heemsbergen W.
        • Al-Mamgani A.
        • Slot A.
        • et al.
        Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival.
        Radiother Oncol. 2014; 110: 104-109
        • Zeitman A.
        • DeSilvio M.
        • Slater J.
        • et al.
        Comparison of conventional-dose vs. high-dose conformal radiation therapy in localized adenocarcinoma of the prostate.
        JAMA. 2005; 294: 1233-1239

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.